A Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

Trial Details

  • 1055 patients will be taking part in this study
  • Condition: Ulcerative Colitis
  • Intervention: Drug: ABT-494 Drug: Placebo
  • Clinic: Dartmouth-Hitchcock Medical Center 1 Medical Center Dr, Lebanon, NH 03756

Summary

This study comprises three sub-studies. The objective of sub-study 1 is to characterize the dose-response, efficacy, and safety of ABT-494 compared to placebo in inducing clinical remission in order to identify the induction dose of ABT-494 for further evaluation in sub-study 2. The objective of sub-study 2 is to evaluate the efficacy and safety of ABT-494 compared to placebo in inducing clinical remission in participants. The objective of sub-study 3 is to evaluate the efficacy and safety of ABT-494 compared to placebo in achieving clinical remission in participants who had a response following induction with ABT-494.

Full Trial Details

Researchers

Dr. Corey Siegel

Dr. corey siegel